Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Next Previous
Search
Trial Profile

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemdisiran (Primary) ; Pozelimab (Primary) ; Pozelimab (Primary)
  • Indications Gastrointestinal disorders; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
  • Focus Pharmacokinetics
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 01 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2022 Planned End Date changed from 20 Jul 2022 to 22 Jun 2022.
    • 18 Apr 2022 Planned primary completion date changed from 20 Jul 2022 to 22 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top